Even though the actual coronavirus season (December to April) is still more than a month away, the situation is already heating up in many European regions. As predicted by SPR and other experts, contact tracing is quickly reaching its limits and face masks are not limiting infections.
(Indeed, a recent US CDC study confirmed that 85% of infected people reported wearing a face mask “always” (70.6%) or “often” (14.4%). Compared to the control group of uninfected people, always wearing a mask did not reduce the risk of infection.)
It is therefore important to offer focused protection to high-risk groups – as recently proposed by the Great Barrington Declaration, signed by leading epidemiologists but nevertheless temporarily delisted by Google – and to implement early and prophylactic treatment protocols.
Covid prophylaxis is particularly important for people at high risk living in epidemically active regions. This is because of the long incubation period of covid-19 (up to 14 days): when people first notice that they contracted the disease, the viral load is already at a maximum and there are often only a few days left to react with an early treatment intervention.
Thus, without covid prophylaxis, one may lose up to two weeks of valuable treatment time.
Covid prophylaxis, which must always be discussed with a doctor, may include zinc, vitamins D and C, quercetin, bromhexine, and possibly aspirin and hydroxychloroquine (HCQ). HCQ was recently confirmed to be safe for covid patients by the European Society of Cardiology and has important anti-viral, anti-platelet, anti-thrombotic and immunomodulatory effects.
Most Western health authorities continue to ignore both the focused protection of high-risk groups and the early and prophylactic treatment of high-risk patients. Renewed partial or total lockdowns, as already introduced in Israel and parts of Spain, are therefore increasingly likely, despite the recent WHO warning describing them as a “terrible global catastrophe”.
It is true that the WHO recently implied a global average covid IFR of about 0.15%, but this value is not applicable to Western countries. A recent Swedish study found an IFR of 0.58% for the entire population, 0.35% for the non-nursing home population, and 0.09% for the <70 population.
With effective early and prophylactic treatment, these values could be even lower.